In this study, based on multi-omics data, we first discussed the differential expression of BCAM in RCC and its relationship with the prognosis, observed that dysregulation of BCAM could be associated with genetic and epigenetic modification, and further found that low expression of BCAM was related to the enrichment of immune infiltration, implying the potential favorable response to immunotherapy among ccRCC. This evidence concerns the gene BCAM and renal cell carcinoma.